In other recent news, Inovio Pharmaceuticals reported significant developments during its Q3 2024 earnings call. The company announced a net loss of $25.2 million but improved its cash position to $84.8 million. The firm's lead product candidate, INO-3107, targeting recurrent respiratory papillomatosis (RRP), demonstrated an 81% clinical response rate in its Phase 1/2 trial. Inovio plans to submit a Biologics License Application (BLA) by mid-2025, following a positive pre-BLA meeting with the FDA.